IDEX Corporation (NYSE: IEX) is trading higher today, with the move aligning with a re-focus on the company’s 2026 earnings setup and a string of recent analyst actions that have kept the name in play. In the past several weeks, analysts have reiterated or refreshed targets—such as BMO Capital’s latest reported target update on March 27, 2026—while earlier in the post-earnings window Argus lifted its stance to Buy and set a $240 price target (Feb. 6, 2026). (benzinga.com)

With the stock now back around the high-$190s area, the market is effectively re-pricing confidence in the company’s 2026 plan rather than waiting for the next quarterly print. After the February 4, 2026 results, management’s messaging emphasized order strength—especially in Health & Science Technologies—alongside 2026 guidance that investors continue to treat as the anchor for near-term upside/downside. (fool.com)

The next key question is whether follow-through buying shows up in volume and whether additional estimate revisions or target changes emerge as the earnings cycle progresses. Traders will also be monitoring company commentary around segment demand (notably HST versus more cyclical end-markets) and capital-return cadence, which has been a recurring support for the equity narrative. (investors.idexcorp.com)